Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 105 entries
Sorted by: Best Match Show Resources per page
Personalised medicine in oncology: questions for the next 20 years.

The Lancet. Oncology

Blay JY, Lacombe D, Meunier F, Stupp R.
PMID: 22554539
Lancet Oncol. 2012 May;13(5):448-9. doi: 10.1016/S1470-2045(12)70156-0.

No abstract available.

Cite
Blay JY, Lacombe D, Meunier F, et al. Personalised medicine in oncology: questions for the next 20 years. Lancet Oncol. 2012;13(5):448-9doi: 10.1016/S1470-2045(12)70156-0.
Blay, J. Y., Lacombe, D., Meunier, F., & Stupp, R. (2012). Personalised medicine in oncology: questions for the next 20 years. The Lancet. Oncology, 13(5), 448-9. https://doi.org/10.1016/S1470-2045(12)70156-0
Blay, Jean-Yves, et al. "Personalised medicine in oncology: questions for the next 20 years." The Lancet. Oncology vol. 13,5 (2012): 448-9. doi: https://doi.org/10.1016/S1470-2045(12)70156-0
Blay JY, Lacombe D, Meunier F, Stupp R. Personalised medicine in oncology: questions for the next 20 years. Lancet Oncol. 2012 May;13(5):448-9. doi: 10.1016/S1470-2045(12)70156-0. PMID: 22554539.
Copy Download .nbib Format: NLM
Oncology practice trends from the national practice benchmark.

Journal of oncology practice

Barr TR, Towle EL.
PMID: 23277766
J Oncol Pract. 2012 Sep;8(5):292-7. doi: 10.1200/JOP.2012.000734.

In 2011, we made predictions on the basis of data from the National Practice Benchmark (NPB) reports from 2005 through 2010. With the new 2011 data in hand, we have revised last year's predictions and projected for the next...

Cite
Barr TR, Towle EL. Oncology practice trends from the national practice benchmark. J Oncol Pract. 2012;8(5):292-7doi: 10.1200/JOP.2012.000734.
Barr, T. R., & Towle, E. L. (2012). Oncology practice trends from the national practice benchmark. Journal of oncology practice, 8(5), 292-7. https://doi.org/10.1200/JOP.2012.000734
Barr, Thomas R, and Towle, Elaine L. "Oncology practice trends from the national practice benchmark." Journal of oncology practice vol. 8,5 (2012): 292-7. doi: https://doi.org/10.1200/JOP.2012.000734
Barr TR, Towle EL. Oncology practice trends from the national practice benchmark. J Oncol Pract. 2012 Sep;8(5):292-7. doi: 10.1200/JOP.2012.000734. PMID: 23277766; PMCID: PMC3439229.
Copy Download .nbib Format: NLM
A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.

Nature reviews. Clinical oncology

Yurkovich JT, Tian Q, Price ND, Hood L.
PMID: 31619755
Nat Rev Clin Oncol. 2020 Mar;17(3):183-194. doi: 10.1038/s41571-019-0273-6. Epub 2019 Oct 16.

Cancer encompasses a complex, heterogeneous and dynamic group of diseases that arise from perturbations to multiple biological networks within the body. A systems biology-based approach would help to decipher this complexity, to deeply characterize the pathophysiology of the disease...

Cite
Yurkovich JT, Tian Q, Price ND, et al. A systems approach to clinical oncology uses deep phenotyping to deliver personalized care. Nat Rev Clin Oncol. 2019;17(3):183-194doi: 10.1038/s41571-019-0273-6.
Yurkovich, J. T., Tian, Q., Price, N. D., & Hood, L. (2020). A systems approach to clinical oncology uses deep phenotyping to deliver personalized care. Nature reviews. Clinical oncology, 17(3), 183-194. https://doi.org/10.1038/s41571-019-0273-6
Yurkovich, James T, et al. "A systems approach to clinical oncology uses deep phenotyping to deliver personalized care." Nature reviews. Clinical oncology vol. 17,3 (2020): 183-194. doi: https://doi.org/10.1038/s41571-019-0273-6
Yurkovich JT, Tian Q, Price ND, Hood L. A systems approach to clinical oncology uses deep phenotyping to deliver personalized care. Nat Rev Clin Oncol. 2020 Mar;17(3):183-194. doi: 10.1038/s41571-019-0273-6. Epub 2019 Oct 16. PMID: 31619755.
Copy Download .nbib Format: NLM
To all involved - we have a problem.

Nature reviews. Clinical oncology

Romero D.
PMID: 29880897
Nat Rev Clin Oncol. 2018 Jul;15(7):397. doi: 10.1038/s41571-018-0052-9.

No abstract available.

Cite
Romero D. To all involved - we have a problem. Nat Rev Clin Oncol. 2018;15(7):397doi: 10.1038/s41571-018-0052-9.
Romero, D. (2018). To all involved - we have a problem. Nature reviews. Clinical oncology, 15(7), 397. https://doi.org/10.1038/s41571-018-0052-9
Romero, Diana. "To all involved - we have a problem." Nature reviews. Clinical oncology vol. 15,7 (2018): 397. doi: https://doi.org/10.1038/s41571-018-0052-9
Romero D. To all involved - we have a problem. Nat Rev Clin Oncol. 2018 Jul;15(7):397. doi: 10.1038/s41571-018-0052-9. PMID: 29880897.
Copy Download .nbib Format: NLM
Evaluation of Oncology Trial Results Reporting Over a 10-Year Period.

JAMA network open

Liu X, Zhang Y, Li WF, Vokes E, Sun Y, Le QT, Ma J.
PMID: 34028549
JAMA Netw Open. 2021 May 03;4(5):e2110438. doi: 10.1001/jamanetworkopen.2021.10438.

IMPORTANCE: Unreported clinical trial results represent a violation of human rights. Oncology trials account for nearly 30% of interventional biopharmaceutical clinical studies registered on ClinicalTrials.gov and are the most numerous among all disciplines.OBJECTIVE: To analyze the reporting of results...

Cite
Liu X, Zhang Y, Li WF, et al. Evaluation of Oncology Trial Results Reporting Over a 10-Year Period. JAMA Netw Open. 2021;4(5):e2110438doi: 10.1001/jamanetworkopen.2021.10438.
Liu, X., Zhang, Y., Li, W. F., Vokes, E., Sun, Y., Le, Q. T., & Ma, J. (2021). Evaluation of Oncology Trial Results Reporting Over a 10-Year Period. JAMA network open, 4(5), e2110438. https://doi.org/10.1001/jamanetworkopen.2021.10438
Liu, Xu, et al. "Evaluation of Oncology Trial Results Reporting Over a 10-Year Period." JAMA network open vol. 4,5 (2021): e2110438. doi: https://doi.org/10.1001/jamanetworkopen.2021.10438
Liu X, Zhang Y, Li WF, Vokes E, Sun Y, Le QT, Ma J. Evaluation of Oncology Trial Results Reporting Over a 10-Year Period. JAMA Netw Open. 2021 May 03;4(5):e2110438. doi: 10.1001/jamanetworkopen.2021.10438. PMID: 34028549; PMCID: PMC8144925.
Copy Download .nbib Format: NLM
Medical oncology job satisfaction: Results of a global survey.

Seminars in oncology

Raphael MJ, Fundytus A, Hopman WM, Vanderpuye V, Seruga B, Lopes G, Hammad N, Sengar M, Brundage MD, Sullivan R, Booth CM.
PMID: 30685074
Semin Oncol. 2019 Feb;46(1):73-82. doi: 10.1053/j.seminoncol.2018.12.006. Epub 2019 Jan 02.

BACKGROUND: While physician burnout is increasingly recognized, little is known about medical oncologist job satisfaction, and the factors associated with low satisfaction. Here, we report the results of an international survey of medical oncologists.METHODS: An online survey was distributed...

Cite
Raphael MJ, Fundytus A, Hopman WM, et al. Medical oncology job satisfaction: Results of a global survey. Semin Oncol. 2019;46(1):73-82doi: 10.1053/j.seminoncol.2018.12.006.
Raphael, M. J., Fundytus, A., Hopman, W. M., Vanderpuye, V., Seruga, B., Lopes, G., Hammad, N., Sengar, M., Brundage, M. D., Sullivan, R., & Booth, C. M. (2019). Medical oncology job satisfaction: Results of a global survey. Seminars in oncology, 46(1), 73-82. https://doi.org/10.1053/j.seminoncol.2018.12.006
Raphael, Michael J, et al. "Medical oncology job satisfaction: Results of a global survey." Seminars in oncology vol. 46,1 (2019): 73-82. doi: https://doi.org/10.1053/j.seminoncol.2018.12.006
Raphael MJ, Fundytus A, Hopman WM, Vanderpuye V, Seruga B, Lopes G, Hammad N, Sengar M, Brundage MD, Sullivan R, Booth CM. Medical oncology job satisfaction: Results of a global survey. Semin Oncol. 2019 Feb;46(1):73-82. doi: 10.1053/j.seminoncol.2018.12.006. Epub 2019 Jan 02. PMID: 30685074.
Copy Download .nbib Format: NLM
The 24th annual David A. Karnofsky memorial lecture. Progress and prospects in cancer treatment: the Karnofsky legacy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Krakoff IH.
PMID: 8113852
J Clin Oncol. 1994 Feb;12(2):432-8. doi: 10.1200/JCO.1994.12.2.432.

No abstract available.

Cite
Krakoff IH. The 24th annual David A. Karnofsky memorial lecture. Progress and prospects in cancer treatment: the Karnofsky legacy. J Clin Oncol. 1994;12(2):432-8doi: 10.1200/JCO.1994.12.2.432.
Krakoff, I. H. (1994). The 24th annual David A. Karnofsky memorial lecture. Progress and prospects in cancer treatment: the Karnofsky legacy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12(2), 432-8. https://doi.org/10.1200/JCO.1994.12.2.432
Krakoff, I H. "The 24th annual David A. Karnofsky memorial lecture. Progress and prospects in cancer treatment: the Karnofsky legacy." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 12,2 (1994): 432-8. doi: https://doi.org/10.1200/JCO.1994.12.2.432
Krakoff IH. The 24th annual David A. Karnofsky memorial lecture. Progress and prospects in cancer treatment: the Karnofsky legacy. J Clin Oncol. 1994 Feb;12(2):432-8. doi: 10.1200/JCO.1994.12.2.432. PMID: 8113852.
Copy Download .nbib Format: NLM
Psychological research in pediatric oncology.

Journal of pediatric psychology

Kazak AE.
PMID: 8340841
J Pediatr Psychol. 1993 Jun;18(3):313-8. doi: 10.1093/jpepsy/18.3.313.

No abstract available.

Cite
Kazak AE. Psychological research in pediatric oncology. J Pediatr Psychol. 1993;18(3):313-8doi: 10.1093/jpepsy/18.3.313.
Kazak, A. E. (1993). Psychological research in pediatric oncology. Journal of pediatric psychology, 18(3), 313-8. https://doi.org/10.1093/jpepsy/18.3.313
Kazak, A E. "Psychological research in pediatric oncology." Journal of pediatric psychology vol. 18,3 (1993): 313-8. doi: https://doi.org/10.1093/jpepsy/18.3.313
Kazak AE. Psychological research in pediatric oncology. J Pediatr Psychol. 1993 Jun;18(3):313-8. doi: 10.1093/jpepsy/18.3.313. PMID: 8340841.
Copy Download .nbib Format: NLM
What's new in TNM?.

Pathology, research and practice

Hermanek P.
PMID: 8065994
Pathol Res Pract. 1994 Jan;190(1):97-102. doi: 10.1016/S0344-0338(11)80505-4.

As other parameters of tumor classification, TNM as well can never be considered definitive because advances in diagnosis and treatment as well as in knowledge of prognostic factors require adaption of current classifications. On the other side, the need...

Cite
Hermanek P. What's new in TNM?. Pathol Res Pract. 1994;190(1):97-102doi: 10.1016/S0344-0338(11)80505-4.
Hermanek, P. (1994). What's new in TNM?. Pathology, research and practice, 190(1), 97-102. https://doi.org/10.1016/S0344-0338(11)80505-4
Hermanek, P. "What's new in TNM?." Pathology, research and practice vol. 190,1 (1994): 97-102. doi: https://doi.org/10.1016/S0344-0338(11)80505-4
Hermanek P. What's new in TNM?. Pathol Res Pract. 1994 Jan;190(1):97-102. doi: 10.1016/S0344-0338(11)80505-4. PMID: 8065994.
Copy Download .nbib Format: NLM
Leader in war on cancer looks ahead: talking with Vincent T. DeVita, Jr, MD.

JAMA

Devita VT.
PMID: 7837381
JAMA. 1995 Feb 15;273(7):525-7. doi: 10.1001/jama.273.7.525.

No abstract available.

Cite
Devita VT. Leader in war on cancer looks ahead: talking with Vincent T. DeVita, Jr, MD. JAMA. 1995;273(7):525-7doi: 10.1001/jama.273.7.525.
Devita, V. T. (1995). Leader in war on cancer looks ahead: talking with Vincent T. DeVita, Jr, MD. JAMA, 273(7), 525-7. https://doi.org/10.1001/jama.273.7.525
Devita, V T. "Leader in war on cancer looks ahead: talking with Vincent T. DeVita, Jr, MD." JAMA vol. 273,7 (1995): 525-7. doi: https://doi.org/10.1001/jama.273.7.525
Devita VT. Leader in war on cancer looks ahead: talking with Vincent T. DeVita, Jr, MD. JAMA. 1995 Feb 15;273(7):525-7. doi: 10.1001/jama.273.7.525. PMID: 7837381.
Copy Download .nbib Format: NLM
Technology and precision therapy delivery in childhood cancer.

Current opinion in pediatrics

Tydings C, Kim A.
PMID: 31876621
Curr Opin Pediatr. 2020 Feb;32(1):1-6. doi: 10.1097/MOP.0000000000000865.

PURPOSE OF REVIEW: The purpose of this review is to describe current advances in pediatric precision therapy through innovations in technology and engineering. A multimodal approach of chemotherapy, surgery and/or radiation therapy has improved survival outcomes for pediatric cancer...

Cite
Tydings C, Kim A. Technology and precision therapy delivery in childhood cancer. Curr Opin Pediatr. 2020;32(1):1-6doi: 10.1097/MOP.0000000000000865.
Tydings, C., & Kim, A. (2020). Technology and precision therapy delivery in childhood cancer. Current opinion in pediatrics, 32(1), 1-6. https://doi.org/10.1097/MOP.0000000000000865
Tydings, Caitlin, and Kim, AeRang. "Technology and precision therapy delivery in childhood cancer." Current opinion in pediatrics vol. 32,1 (2020): 1-6. doi: https://doi.org/10.1097/MOP.0000000000000865
Tydings C, Kim A. Technology and precision therapy delivery in childhood cancer. Curr Opin Pediatr. 2020 Feb;32(1):1-6. doi: 10.1097/MOP.0000000000000865. PMID: 31876621.
Copy Download .nbib Format: NLM
Gene-editing pipeline takes off.

Nature reviews. Drug discovery

Mullard A.
PMID: 32415249
Nat Rev Drug Discov. 2020 Jun;19(6):367-372. doi: 10.1038/d41573-020-00096-y.

No abstract available.

Cite
Mullard A. Gene-editing pipeline takes off. Nat Rev Drug Discov. 2020;19(6):367-372doi: 10.1038/d41573-020-00096-y.
Mullard, A. (2020). Gene-editing pipeline takes off. Nature reviews. Drug discovery, 19(6), 367-372. https://doi.org/10.1038/d41573-020-00096-y
Mullard, Asher. "Gene-editing pipeline takes off." Nature reviews. Drug discovery vol. 19,6 (2020): 367-372. doi: https://doi.org/10.1038/d41573-020-00096-y
Mullard A. Gene-editing pipeline takes off. Nat Rev Drug Discov. 2020 Jun;19(6):367-372. doi: 10.1038/d41573-020-00096-y. PMID: 32415249.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 105 entries